

TGFb inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/TEF8285C3958EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: TEF8285C3958EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "TGF-Beta Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in TGF-Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TGF-Beta Inhibitors Understanding

TGF-Beta Inhibitors: Overview

Transforming growth factor (TGF)- β is a secreted multifunctional cytokine that signals via plasma membrane TGF- β type I and type II receptors and intercellular SMAD transcriptional effectors. Aberrant inter- and intracellular TGF- β signaling can contribute to cancer progression. In normal cells and early stages of cancer, TGF- β can stimulate epithelial growth arrest and elicit a tumor suppressor function. However, in late stages of cancer, when the cytostatic effects of TGF- β in cancer cells are blocked, TGF- β signaling can act as tumor promoter by its ability to stimulate epithelial-to-mesenchymal transition of cancer cells, by stimulating angiogenesis, and by promoting evasion of immune responses.

Transforming growth factor β (TGF- β) is part of a larger superfamily of secreted dimeric multifunctional proteins that also includes activins and bone morphogenetic proteins. It plays an important role in embryogenesis and in maintaining tissue homeostasis in multicellular organisms. TGF- β elicits highly context-dependent effects on many different cell types. Hence, anomalous TGF- β signaling can result in numerous diseases, including cancer. TGF- β signaling can have a dual role in cancer

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TGF-Beta Inhibitors R&D. The therapies under development are focused on novel approaches for TGF-Beta Inhibitors.

In July 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbuis, Adding Lead TGF-beta Asset to Portfolio.

TGF-Beta Inhibitors Emerging Drugs Chapters

This segment of the TGF-Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TGF-Beta Inhibitors Emerging Drugs

Luspatercept - Acceleron Pharma

Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.

Further product details are provided in the report.....

TGF-Beta Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different TGF-Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TGF-Beta Inhibitors

There are approx. 10+ key companies which are developing the TGF-Beta Inhibitors. The companies which have their TGF-Beta Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Luspatercept.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

TGF-Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TGF-Beta Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TGF-Beta Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGF-Beta Inhibitors drugs.

TGF-Beta Inhibitors Report Insights

TGF-Beta Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

TGF-Beta Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing TGF-Beta Inhibitors drugs?

How many TGF-Beta Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for TGF-Beta Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TGF-Beta Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TGF-Beta Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Accelaron Pharma

Isarna Therapeutics

Forbius

Key Products

Luspatercept

ISTH0036

ISTH1106

ISTH0047

ISTH1047

AVID 200

Contents

- Introduction
- Executive Summary
- TGF-Beta Inhibitors: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- TGF-Beta Inhibitors - DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - TGF-Beta Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- TGF-Beta Inhibitors Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Luspatercept - Acceleron Pharma
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- ISTH0036: Isarna Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
 - Comparative Analysis

ISTH1106: Isarna Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

TGF-Beta Inhibitors Key Companies

TGF-Beta Inhibitors Key Products

TGF-Beta Inhibitors- Unmet Needs

TGF-Beta Inhibitors- Market Drivers and Barriers

TGF-Beta Inhibitors- Future Perspectives and Conclusion

TGF-Beta Inhibitors Analyst Views

TGF-Beta Inhibitors Key Companies

List Of Tables

LIST OF TABLES

Table 1 Total Products for TGF-Beta Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for TGF-Beta Inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: TGFb inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/TEF8285C3958EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TEF8285C3958EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970